Concepedia

Margherita Rimini

MR

46

Publications

1.3K

Citations

21

H-Index

2005

Active since

Affiliations

Istituti di Ricovero e Cura a Carattere Scientifico(Current)

Vita-Salute San Raffaele University

Istituto Oncologico Veneto

Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele

Azienda Ospedaliera Universitaria Pisana

Margherita Rimini is an author at Istituti di Ricovero e Cura a Carattere Scientifico specializing in medicine, pathology, and radiation oncology.

ORCID

Top concepts

Publications per year

2005–2024

46

Publications

46

Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis

Margherita Rimini, Lorenza Rimassa, Kazuomi Ueshima et al. · ESMO Open · 2022 · 124 citations · Full text

Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population

Andrea Casadei‐Gardini, Margherita Rimini, Toshifumi Tada et al. · European Journal of Cancer · 2022 · 123 citations · Full text

, , +8

Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data

Margherita Rimini, Lorenzo Fornaro, Sara Lonardi et al. · Liver International · 2023 · 110 citations · Full text

Lenvatinib versus sorafenib in first‐line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis

Andrea Casadei‐Gardini, Mario Scartozzi, Toshifumi Tada et al. · Liver International · 2021 · 60 citations

Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients

Mara Persano, Margherita Rimini, Toshifumi Tada et al. · European Journal of Cancer · 2023 · 50 citations · Full text

Rows per page

1–5 of 46